Fmoc-L-MeSer(Bzl)-OH

Fmoc-L-MeSer(Bzl)-OH is an Fmoc-protected L-serine derivative bearing a methyl substituent at the β-carbon and a benzyl-protected side-chain hydroxyl, giving a chiral amino acid building block with orthogonal protection for peptide assembly and side-chain manipulation. The molecule contains an Fmoc carbamate on the α-amino group, a free carboxylic acid for coupling, and a benzyl ether that can be removed under hydrogenolysis or strong ether-cleaving conditions to regenerate the serine-like hydroxyl functionality. The β-methyl substitution and benzyl ether alter steric and electronic properties relative to canonical serine, which can influence coupling behavior, protecting-group stability, and subsequent derivatization of the side chain. As a chiral amino acid intermediate, it is structured to support protected amino acid synthesis, stereochemically defined peptide construction, and downstream functionalization of the side-chain alcohol after deprotection.

1. Peptide Synthesis

Fmoc-L-MeSer(Bzl)-OH is applied in solid-phase peptide synthesis where the Fmoc carbamate enables controlled N-terminal protection and base-mediated Fmoc removal to expose the α-amine for iterative peptide coupling. The free carboxylic acid and the L-stereocenter provide a stereodefined residue for incorporation into peptide chains, while the benzyl-protected side-chain hydroxyl prevents undesired side reactions during amide bond formation. The β-methyl substitution can be used to tune local sterics around the residue, supporting the construction of peptides that probe conformational effects or mimic methylated serine motifs. Side-chain deprotection can then regenerate the hydroxyl for phosphorylation-mimetic chemistry, ester formation, or further functional group installation, linking protected amino acid synthesis to peptide analog generation.

2. Side-Chain Functionalization

Fmoc-L-MeSer(Bzl)-OH supports amino acid derivatization strategies targeting the serine-like alcohol functionality, with the benzyl ether serving as a removable protecting group for controlled timing of side-chain chemistry. The orthogonal combination of Fmoc on nitrogen and benzyl on oxygen enables selective deprotection sequences, allowing peptide assembly to proceed without side-chain interference and later conversion of the liberated hydroxyl into ethers, esters, or other oxygen-linked substituents. The β-methyl stereochemistry can affect reactivity and stereochemical outcomes in downstream transformations that form new stereocenters or introduce substituents at the side-chain oxygen. The resulting functionalized derivatives can be used as biochemical research intermediates and as building blocks for peptidomimetics where hydroxyl-bearing motifs are required for molecular recognition or chemical labeling.

3. Chemical Biology Labeling

Fmoc-L-MeSer(Bzl)-OH is suitable for chemical biology workflows that require incorporation of a protected hydroxyl-bearing residue into peptides for subsequent conjugation or tagging chemistry. The protected amino acid format allows site-specific placement within peptide scaffolds, and the benzyl-protected side-chain oxygen can be unveiled to generate a handle for coupling to electrophiles, forming oxygen-linked conjugates, or enabling attachment of imaging or affinity tags under controlled conditions. The methylated serine motif can be used to model post-translationally modified environments or to study how subtle changes in side-chain sterics affect labeling efficiency and molecular recognition. Downstream derivatization of the regenerated hydroxyl supports preparation of labeled peptide probes, bioconjugation-ready intermediates, and analytical standards for monitoring conjugation outcomes.

4. Peptidomimetics And SAR Studies

Fmoc-L-MeSer(Bzl)-OH is used in peptidomimetic construction and structure-activity relationship studies where a methylated serine-like residue provides a stereodefined element for scaffold optimization. The chiral α-amino acid core and protected functional groups allow systematic synthesis of analog series in which side-chain oxygen chemistry is introduced after assembly, facilitating parallel preparation of hydroxyl-functional variants. The β-methyl substitution can modulate backbone preferences and side-chain orientation, enabling SAR investigations that correlate residue-level structural changes with physicochemical properties such as polarity and hydrogen-bonding patterns. The compound's protected form also supports combinatorial peptide analog synthesis by maintaining orthogonal protection during chain assembly and enabling late-stage side-chain modification for rapid generation of structure-defined libraries.

5. Pharmaceutical Intermediate Preparation

Fmoc-L-MeSer(Bzl)-OH is relevant to pharmaceutical intermediate preparation and process chemistry development for manufacturing routes that require stable, isolable protected amino acid building blocks. The Fmoc-protected amine and benzyl-protected hydroxyl provide protection against premature functional-group reactivity during multistep synthesis, while the free carboxylic acid supports conversion into activated coupling forms compatible with peptide-building workflows. The defined L-configuration and methylated side-chain structure make it suitable for producing stereochemically consistent peptide intermediates used in fine chemical synthesis and specialty chemical production. Deprotection and downstream functionalization strategies can be integrated into a controlled sequence to yield hydroxyl-bearing intermediates for further derivatization, aligning protected amino acid chemistry with industrially oriented synthetic planning.

1. Cell-based adhesion assays for isolation of snake venom’s integrin antagonists

2. Crystal Structure of BamB from Pseudomonas aeruginosa and Functional Evaluation of Its Conserved Structural Features

3. Identification, Localization in the Central Nervous System and Novel Myostimulatory Effect of Allatostatins in Tenebrio molitor Beetle

4. Implications of ligand-receptor binding kinetics on GLP-1R signalling

5. Relatedness of antibodies to peptides containing homocitrulline or citrulline in patients with rheumatoid arthritis